Critical

Paraneoplastic pemphigus

Severe autoimmune blistering · Dermatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A severe autoimmune blistering disease driven by an underlying malignancy (often lymphoma/CLL), dominated by refractory, painful mucositis with polymorphous skin lesions, and a risk of fatal airway involvement (bronchiolitis obliterans). Immunosuppression and tumour treatment are key.

Figures & algorithms

Pemphigus vs pemphigoid
Pemphigus vs pemphigoid

Assessment

Investigations

  • Severe, treatment-resistant oral/conjunctival mucositis + polymorphous skin
  • Biopsy and specific antibodies; CT to find an underlying malignancy
  • Assess for respiratory involvement

Management

  • Urgent dermatology and oncology/haematology involvement
  • Immunosuppression (corticosteroids and steroid-sparing agents)
  • Treat the underlying malignancy
  • Intensive supportive/skin/mucosal care; monitor the airway
  • Recognise the high mortality

Drugs & doses

Immunosuppression
Treat underlying malignancy
Supportive care

Disposition

Dermatology/oncology.

Severe refractory mucositis with skin blistering is paraneoplastic pemphigus until proven otherwise - hunt for a lymphoma and watch the airway.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.